mRNA-1647 Cytomegalovirus (CMV) Vaccine - Teen Arm

STUDY BASICS

Was your child assigned female at birth? Are they 16-17 years old? You and your child may be eligible for a research study to learn how study vaccine mRNA-1647 works in your body. Compensation is provided.

STUDY PURPOSE

Cytomegalovirus (CMV) is the #1 infection that causes birth defects in the U.S. There is currently no approved vaccine or treatment against this virus.  We are looking for healthy, non-pregnant, female volunteers between 16-17 years of age to participate in a research study of an investigational vaccine to prevent cytomegalovirus (CMV) infection. This is an mRNA vaccine developed with the technology that was used to develop COVID vaccines. CMV is a common virus that can spread easily through an infected person’s saliva or other body fluids such as blood, urine, and breast milk. It is unusual for a CMV infection in a healthy person to cause illness. However, if a pregnant woman has a CMV infection, it may be passed to her unborn child. Infants born with CMV infection can have severe symptoms. 

COULD THIS STUDY BE RIGHT FOR YOUR CHILD?

Eligible participants:

• Are children ages 16-17
• Were assigned female at birth 

WHAT PARTICIPANTS CAN EXPECT

If your child participates in this study, they will receive a total of 3 separate injections of either mRNA-1647 or placebo into the muscle in their upper arm over a period of 6 months. All 3 injections will be either mRNA-1647 or placebo depending on what the computer initially decided. After each injection, you and your child will remain at the study site for an observation period of approximately 30 to 45 minutes so that the study doctor or a member of the study team can observe whether your child has any immediate reactions to the study vaccine. 

You and your child may not have to return to the site for all 14 visits. You will be contacted approximately 21 times for safety data collection either by telephone or through receipt of electronic diary (eDiary) safety survey messages.